IL164652A0 - Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside - Google Patents
Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycosideInfo
- Publication number
- IL164652A0 IL164652A0 IL16465204A IL16465204A IL164652A0 IL 164652 A0 IL164652 A0 IL 164652A0 IL 16465204 A IL16465204 A IL 16465204A IL 16465204 A IL16465204 A IL 16465204A IL 164652 A0 IL164652 A0 IL 164652A0
- Authority
- IL
- Israel
- Prior art keywords
- blocker
- administration
- calcium channel
- cardiac glycoside
- adenosine agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37376602P | 2002-04-18 | 2002-04-18 | |
PCT/US2003/012043 WO2003088978A1 (en) | 2002-04-18 | 2003-04-18 | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164652A0 true IL164652A0 (en) | 2005-12-18 |
Family
ID=29251078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16465204A IL164652A0 (en) | 2002-04-18 | 2004-10-18 | Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
Country Status (17)
Country | Link |
---|---|
US (3) | US7005425B2 (ru) |
EP (1) | EP1494685B1 (ru) |
JP (1) | JP2005530736A (ru) |
KR (1) | KR20040106354A (ru) |
CN (2) | CN1646142A (ru) |
AT (1) | ATE418991T1 (ru) |
AU (1) | AU2003235466C1 (ru) |
CA (1) | CA2482928A1 (ru) |
DE (1) | DE60325572D1 (ru) |
ES (1) | ES2318129T3 (ru) |
IL (1) | IL164652A0 (ru) |
MX (1) | MXPA04010285A (ru) |
NO (1) | NO20045005L (ru) |
NZ (1) | NZ536001A (ru) |
RU (1) | RU2332220C2 (ru) |
WO (1) | WO2003088978A1 (ru) |
ZA (1) | ZA200408411B (ru) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2359688B1 (en) | 1999-03-23 | 2015-05-27 | Hibernation Therapeutics, a KF LLC | Organ arrest, protection and preservation |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
US7713946B2 (en) * | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
DE60325572D1 (de) * | 2002-04-18 | 2009-02-12 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
GB2436255B (en) * | 2002-12-23 | 2007-11-28 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery |
JP2008505967A (ja) * | 2004-07-12 | 2008-02-28 | シーブイ・セラピューティクス・インコーポレイテッド | A1アデノシンレセプターアゴニストの製造方法 |
US20060019954A1 (en) * | 2004-07-20 | 2006-01-26 | Cedars-Sinai Medical Center | Method for reducing the likelihood of the occurrence of cardiac arrhythmias |
US7300923B2 (en) * | 2004-08-30 | 2007-11-27 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
EP1802775B1 (en) | 2004-09-14 | 2010-05-26 | The Regents of the University of Colorado | Method for treatment with bucindolol based on genetic targeting |
US7822474B2 (en) * | 2005-11-30 | 2010-10-26 | Cedars-Sinai Medical Center | Methods for the prediction of arrhythmias and prevention of sudden cardiac death |
KR101494125B1 (ko) | 2006-02-03 | 2015-02-16 | 길리애드 사이언시즈, 인코포레이티드 | A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법 |
JP2009538834A (ja) | 2006-05-29 | 2009-11-12 | ハイバーネイション セラピューティクス リミテッド | 組織維持の改善 |
KR20140108346A (ko) | 2006-07-25 | 2014-09-05 | 하이버네이션 테라퓨틱스 리미티드 | 외상 치료법 |
CA2717162A1 (en) | 2007-03-02 | 2008-09-12 | Hibernation Therapeutics Limited | Transplants |
SI2234614T1 (sl) * | 2007-12-21 | 2013-01-31 | Aop Orphan Pharmaceuticals Ag | Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorja |
AU2009296235A1 (en) * | 2008-09-29 | 2010-04-01 | Gilead Sciences, Inc. | Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods |
GB0903299D0 (en) | 2009-02-26 | 2009-04-08 | Guys And St Thomas Nhs Foundat | Composition and methods |
CA2835771C (en) * | 2009-03-18 | 2017-01-24 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
US20110039799A1 (en) | 2009-08-14 | 2011-02-17 | Gilead Palo Alto, Inc. | A1 adenosine receptor agonist polymorphs |
EA025415B1 (ru) | 2010-01-11 | 2016-12-30 | Инотек Фармасьютикалз Корпорейшн | Комбинация, набор и способ снижения внутриглазного давления |
PL2555776T3 (pl) * | 2010-03-19 | 2017-08-31 | Inotek Pharmaceuticals Corporation | Kompozycje połączenia agonistów receptora adenozyny A<sub>1</sub> i nieselektywnego blokera receptora beta-adrenergicznego do obniżania ciśnienia wewnątrzgałkowego |
JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
SG10201701343QA (en) | 2012-01-26 | 2017-04-27 | Inotek Pharmaceuticals Corp | Anhydrous Polymorphs of (2r,3s,4r,5r)-5-(6-(Cyclopentylamino)-9h-Purin-9-Yl)-3,4-Dihydroxytetrahydrofuran-2-Yl) } Methyl Nitrate and Processes of Preparation Thereof |
AU2014239222A1 (en) | 2013-03-15 | 2015-10-01 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
CN105722516A (zh) | 2013-07-17 | 2016-06-29 | 低温药理Kf有限公司 | 一种用于治疗感染、败血症和损伤的方法 |
AU2014361813A1 (en) * | 2013-12-13 | 2016-07-28 | Ralph ANKENMAN | Compositions and methods for treating dysregulated systems |
GB2581301A (en) | 2016-02-01 | 2020-08-12 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy to manage atrial arrhythmias including atrial fibrillation |
CN106370754B (zh) * | 2016-11-07 | 2019-03-08 | 西安科技大学 | 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法 |
EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION |
WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
AU722110B2 (en) * | 1996-06-28 | 2000-07-20 | Merck & Co., Inc. | Pharmaceutical preparation |
US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
EP0966274B1 (en) * | 1997-01-31 | 2002-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
CO5180581A1 (es) * | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
US6576620B2 (en) | 1999-12-03 | 2003-06-10 | Cv Therapeutics, Inc. | Method of identifying partial adenosine A1 receptor agonists |
IL154652A0 (en) * | 2000-09-08 | 2003-09-17 | Cv Therapeutics Inc | Purine ribosides as antiarrhythmics |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
DE60325572D1 (de) * | 2002-04-18 | 2009-02-12 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
-
2003
- 2003-04-18 DE DE60325572T patent/DE60325572D1/de not_active Expired - Lifetime
- 2003-04-18 US US10/418,654 patent/US7005425B2/en not_active Expired - Fee Related
- 2003-04-18 KR KR10-2004-7016764A patent/KR20040106354A/ko active IP Right Grant
- 2003-04-18 EP EP03724098A patent/EP1494685B1/en not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012043 patent/WO2003088978A1/en active Application Filing
- 2003-04-18 AU AU2003235466A patent/AU2003235466C1/en not_active Ceased
- 2003-04-18 CN CNA038086999A patent/CN1646142A/zh active Pending
- 2003-04-18 RU RU2004130826/14A patent/RU2332220C2/ru not_active IP Right Cessation
- 2003-04-18 AT AT03724098T patent/ATE418991T1/de not_active IP Right Cessation
- 2003-04-18 CN CNA2008101711378A patent/CN101385738A/zh active Pending
- 2003-04-18 MX MXPA04010285A patent/MXPA04010285A/es active IP Right Grant
- 2003-04-18 JP JP2003585730A patent/JP2005530736A/ja active Pending
- 2003-04-18 NZ NZ536001A patent/NZ536001A/en not_active IP Right Cessation
- 2003-04-18 CA CA002482928A patent/CA2482928A1/en not_active Abandoned
- 2003-04-18 ES ES03724098T patent/ES2318129T3/es not_active Expired - Lifetime
-
2004
- 2004-10-18 IL IL16465204A patent/IL164652A0/xx unknown
- 2004-10-18 ZA ZA200408411A patent/ZA200408411B/en unknown
- 2004-11-17 NO NO20045005A patent/NO20045005L/no not_active Application Discontinuation
-
2005
- 2005-10-28 US US11/262,025 patent/US7479485B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,731 patent/US20090118221A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1646142A (zh) | 2005-07-27 |
WO2003088978A1 (en) | 2003-10-30 |
JP2005530736A (ja) | 2005-10-13 |
AU2003235466C1 (en) | 2008-03-20 |
KR20040106354A (ko) | 2004-12-17 |
US20030216349A1 (en) | 2003-11-20 |
ATE418991T1 (de) | 2009-01-15 |
US20090118221A1 (en) | 2009-05-07 |
ES2318129T3 (es) | 2009-05-01 |
AU2003235466A1 (en) | 2003-11-03 |
ZA200408411B (en) | 2006-02-22 |
CA2482928A1 (en) | 2003-10-30 |
US7479485B2 (en) | 2009-01-20 |
RU2332220C2 (ru) | 2008-08-27 |
NZ536001A (en) | 2006-05-26 |
CN101385738A (zh) | 2009-03-18 |
US7005425B2 (en) | 2006-02-28 |
DE60325572D1 (de) | 2009-02-12 |
RU2004130826A (ru) | 2005-05-10 |
EP1494685A1 (en) | 2005-01-12 |
NO20045005L (no) | 2004-11-17 |
EP1494685B1 (en) | 2008-12-31 |
MXPA04010285A (es) | 2005-02-03 |
US20060052333A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL164652A0 (en) | Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside | |
IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
WO2004043377A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
ES2158778A1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
EP0781136A4 (en) | COMPOUNDS AND METHODS FOR TREATING CANCER | |
WO2004006859A3 (en) | Platinum compound | |
AU1810001A (en) | Compounds, compositions, and methods for stimulating neuronal growth and elongation | |
HK1082663A1 (en) | Extract with anti-tumor and anti-poisonous activity | |
AU2001292579A1 (en) | Methods and compounds for treating proliferative diseases | |
MY129445A (en) | Compositions for treating inflammatory response | |
ES2088771A1 (es) | Metodo para mejorar la acividad reproductora en verracos utilizando alimento para los verracos reproductores. | |
WO2004012746A3 (en) | New uses for inhibitors of inosine monophosphate dehydrogenase | |
WO2001045684A3 (en) | Formulations of adenosine a1 agonists | |
PL376346A1 (en) | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
GB9924941D0 (en) | Treatment of dyskinesia | |
EP1152760A4 (en) | USE OF 4-AMINO PYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | |
WO2005094282B1 (en) | Combination therapy comprising cloretazinetm | |
ZA988009B (en) | Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. | |
IL154652A0 (en) | Purine ribosides as antiarrhythmics | |
AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
EP0904094A4 (en) | TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE | |
SI1196172T1 (sl) | (S,S)-reboksetin za zdravljenje kronicne bolecine | |
WO2000061183A3 (en) | Verotoxin treatment of lymphomas |